Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by enGene Holdings Inc.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Announces the Resignation of its Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Present at the Jefferies Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Names Amy Pott as Chief Global Commercialization Officer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Participate in the Leerink Partners Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Announces $60 Million Private Placement Financing
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.